Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)). Reference standards of Cerdulatinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object ( [pname] => Cerdulatinib - API Standards [catalogue_number] => PA 03 3830000 [category_ids] => ,75,76,78,70,82, [chemical_name] => [weight] => 445.54 [form] => C20H27N7O3S [cas] => 1198300-79-6 [pslug] => 1198300-79-6-cerdulatinib-api-pa033830000 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 03 3830000
CAS :
Molecular Formula : C20H27N7O3S
Molecular Weight : 445.54
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....